18223 Long-term proactive management of psoriasis vulgaris with fixed-dose combination of 0.005% calcipotriene and 0.064% betamethasone dipropionate foam: Results of a phase III randomized controlled trial

Lebwohl, Mark; Lacour, Jean‐Philippe; Liljedahl, Monika; Lynde, Charles; Mørch, Marie Holst; Snel-Prentø, Anja Marieke; Thaçi, Diamant; Warren, Richard B.

doi:10.1016/j.jaad.2020.06.919

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a comparative trial of psoriasis vulgaris, the 2-compound-gel formulation showed tolerability and cost-effectiveness superior to that of a mono-formulation [13, 35]. Recently, a phase 3 trial comparing the efficacy and safety of the Cal/BD fixed-dose combination aerosol foam versus placebo showed that the proactive twice weekly management of psoriasis resulted in a 43% (95% CI 0.47–0.57) reduction in the risk of experiencing a first relapse compared to subjects in the placebo (vehicle) group ( p < 0.001) [36].…”

Section: Treatment Pathwaymentioning

confidence: 99%

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway

Maul

Anzengruber

Conrad³

et al. 2021

Dermatology

View full text Add to dashboard Cite

Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choice of a suitable topical treatment, the formulation matters and not just the active substances. This expert opinion paper was developed via a non-structured consensus process by Swiss dermatologists in hospitals and private practices to illustrate the current treatment options to general practitioners and dermatologists in Switzerland. Defining treatment goals together with the patient is crucial and increases treatment adherence. Patients’ personal preferences and pre-existing experiences should be considered and their satisfaction with treatment and outcome regularly assessed. During the induction phase of “classical” mild-to-moderate psoriasis, the fixed combination of topical calcipotriol (Cal) 50 μg/g and betamethasone dipropionate (BD) 0.5 mg/g once daily is frequently used for 4–8 weeks. During the maintenance phase, a twice weekly (proactive) management has proved to reduce the risk of relapse. Of the fixed combinations, Cal/BD aerosol foam is the most effective formulation. However, the individual choice of formulation should be based on a patient’s preference and the location of the psoriatic plaques. Tailored recommendations are given for the topical management of specific areas (scalp, facial, intertriginous/genital, or palmoplantar lesions), certain symptoms (hyperkeratotic or hyperinflammatory forms) as well as during pregnancy or a period of breastfeeding. As concomitant basic therapy, several emollients are recommended. If topical treatment alone does not appear to be sufficient, the regimen should be escalated according to the Swiss S1-guideline for the systemic treatment of psoriasis.

show abstract

Section: Treatment Pathwaymentioning

confidence: 99%